KSA Molecular Diagnostics Market Outlook to 2028

KSA Molecular Diagnostics Market Overview

The KSA molecular diagnostics market has experienced rapid growth in recent years reaching a market size of USD 530 Mn, driven by increasing healthcare expenditures, advancements in molecular testing technologies, and a growing demand for personalized medicine. The market has also benefited from an increased focus on infectious disease diagnostics, particularly following the COVID-19 pandemic, which heightened the need for advanced diagnostic tools.

Major urban centers like Riyadh, Jeddah, and Dammam serve as key hubs for molecular diagnostic services, with numerous healthcare facilities adopting state-of-the-art testing methods to improve patient outcomes. Additionally, the government's Vision 2030 initiative, aimed at transforming the healthcare sector, plays a crucial role in the markets expansion by promoting modern healthcare infrastructure and boosting investment in cutting-edge medical technologies.

The Saudi Food and Drug Authority (SFDA) plays a critical role in regulating molecular diagnostics to ensure safety, efficacy, and compliance with international standards. The SFDA mandates that diagnostic equipment, including molecular diagnostics technologies such as PCR and NGS, meet stringent quality standards such as ISO 13485 for medical devices and ISO 15189 for medical laboratories.

KSA Molecular Diagnostics Market Segmentation

By Application: The market is segmented by application into infectious diseases, oncology, genetic testing, blood screening and others. Infectious diseases hold the largest market share, driven by the need for accurate and rapid testing for pathogens like SARS-Co V-2, MERS-Co V, and other emerging viruses. Oncology is also witnessing rapid growth due to the increasing prevalence of cancer and the rising use of molecular diagnostics for early detection and personalized treatment.

By Technology: The market is also segmented by technology into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization, and Microarray. PCR remains the most dominant technology, accounting for the largest market share due to its widespread use in detecting infectious diseases and its established presence in healthcare facilities. The ease of use, cost-effectiveness, and speed of PCR tests have cemented its place as the leading technology in the market.

KSA Molecular Diagnostics Market Competitive Landscape

The KSA molecular diagnostics market is competitive, with a blend of international players and local companies providing advanced diagnostic solutions. Major companies such as Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific are key market players, offering a wide array of molecular diagnostic tests and instruments. These companies are at the forefront of technological advancements and have established partnerships with local healthcare providers to ensure their products meet the regions healthcare needs.

Company Name

Establishment Year

Headquarters

Revenue (2023)

Employees

Key Product

R&D Investment

Key Clients

Partnerships

Roche Diagnostics

1896

Switzerland

Abbott Laboratories

1888

USA

Thermo Fisher Scientific

1956

USA

Al Borg Diagnostics

1999

Saudi Arabia

Almana General Hospital

1949

Saudi Arabia

KSA Molecular Diagnostics Industry Analysis

Growth Drivers:

Rising Prevalence of Infectious Diseases: Infectious diseases like COVID-19, MERS, and Tuberculosis continue to challenge the Kingdom of Saudi Arabia (KSA). In 2024, Saudi Arabia reported over 841,469 confirmed cases of COVID-19, with around 9646 deaths. Tuberculosis also remains prevalent, with 3,000 cases reported annually in the country. These figures underscore the demand for advanced molecular diagnostics in tracking and managing infectious diseases. The MERS-Co V virus, which caused 2,613 cases and 941 deaths globally, including cases in Saudi Arabia, further drives the need for robust diagnostics technology in the regionchnological advancements.

Technological Advancements in Next-Generation Sequencing, PCR and AI in Diagnostics: Technological innovations such as Next-Generation Sequencing (NGS), PCR, and AI-based diagnostics are revolutionizing molecular diagnostics in KSA. Saudi Arabia has invested heavily in NGS-based genomic research, with the King Faisal Specialist Hospital (KFSH) performing over 3,000 genomic sequencing tests annually. Real-Time PCR remains central to diagnosing infectious diseases and is widely used across 50+ public and private laboratories in Saudi Arabia. AI is gaining traction in diagnostic applications, including cancer diagnostics, as part of the government's investment in smart healthcare systems.

Increasing Focus on Precision Medicine: Saudi Arabia is increasingly focusing on precision medicine, especially in oncology diagnostics. In 2024, cancer was responsible for nearly 13,339 deaths annually in KSA, with breast and colorectal cancers being the most prevalent. Genetic testing, such as BRCA gene testing for breast cancer, is becoming critical for early diagnosis and treatment plans. Vision 2030 includes substantial investments to enhance oncology services, expanding diagnostic capabilities in precision medicine. Currently, around 30% of hospitals in the country offer some form of genetic testing for cancer.

Market Challenges
:

High Costs of Molecular Diagnostic Technologies: The cost of molecular diagnostic technologies, such as PCR and NGS, remains a significant barrier in Saudi Arabia. These technologies require advanced equipment and consumables, which are costly and difficult for smaller hospitals and clinics to afford. NGS machines and PCR equipment are especially expensive, limiting widespread adoption of lower-budget healthcare facilities. Although the government has made efforts to support the healthcare sector, only a portion of the healthcare budget is allocated to advanced diagnostic tools, which creates challenges for institutions looking to implement cutting-edge molecular diagnostic technologies.

Shortage of Skilled Workforce: Despite advancements in molecular diagnostics, a significant shortage of skilled professionals remains in Saudi Arabia. The country lacks an adequate number of trained laboratory technicians and genetic counselors who are critical to the functioning of molecular diagnostic labs. This gap affects the overall capacity of healthcare facilities to offer advanced diagnostic services. The Ministry of Health has recognized this issue and initiated programs to address the shortage through training and education, but the demand for professionals still outpaces the available workforce, posing a challenge to the sector's growth and effectiveness.

KSA Molecular Diagnostics Market Future Outlook

The KSA molecular diagnostics market is expected to experience continued growth over the forecast period, supported by increasing investments in healthcare infrastructure, the rising prevalence of infectious diseases, and technological advancements in diagnostics. The Saudi government's commitment to enhancing healthcare under Vision 2030 will play a critical role in driving market expansion.

Future Market Opportunities:

Expansion of Genetic Testing Services: Genetic testing services are rapidly expanding in Saudi Arabia, particularly in cancer genomics and pre-natal screening. With nearly 10,000 cancer deaths annually, the demand for genomic testing is growing. Hospitals such as the King Abdullah International Medical Research Center are offering expanded services, performing over 5,000 genomic tests yearly. Pre-natal screening is also gaining momentum, especially with government initiatives promoting maternal healthcare, resulting in over 150,000 prenatal screenings in 2023. The rise in demand offers significant opportunities for further market expansion.

Growth in Point-of-Care Diagnostics: Point-of-care diagnostics (Po C) is becoming increasingly popular in KSA, particularly for infectious diseases. Portable PCR devices, capable of providing results in under an hour, are now available in more than 70% of the country's hospitals. Rapid test kits, especially for COVID-19, have seen high demand, with over 5 million units distributed in the last two years. The Ministry of Health is further supporting Po C diagnostics by integrating them into primary healthcare clinics, aiming to reduce diagnostic times across the country.
Please Note: It will take 5-7 business days to complete the report upon order confirmation